Geneva, April 28 -- International Clinical Trials Registry received information related to the study (KCT0011862) titled 'Effect of an Exercise Program on Metabolic Syndrome in Endometrial Cancer Pati... Read More
Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260416008) titled 'Effect of prophylactic ondansetron on hemodynamic changes in elderly pati... Read More
Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260416004) titled 'Community-Based Interventions to Increase Diabetic Retinopathy Screening ... Read More
Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260416009) titled 'Effects of Exercise Snacks on Cardiorespiratory Fitness, Quality of Life,... Read More
Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260416005) titled 'A Bioequivalence study of a randomized, open-label, single dose, two-way ... Read More
Geneva, April 28 -- International Clinical Trials Registry received information related to the study (TCTR20260416001) titled 'Effect of intravenous hydrocortisone in in-hospital acquire sepsis: a ran... Read More
Geneva, April 28 -- International Clinical Trials Registry received information related to the study (KCT0011861) titled 'Investigating the Effects of Visual Stimuli from Horticultural Plants on Brain... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More